Atossa Therapeutics, Inc

(NASDAQ:ATOS)

Latest On Atossa Therapeutics, Inc (ATOS):

Date/Time Type Description Signal Details
2023-03-22 23:50 ESTNewsAtossa Therapeutics GAAP EPS of -$0.21 beats by $0.01N/A
2023-02-28 16:56 ESTNewsAtossa Therapeutics FY 2022 Earnings PreviewN/A
2023-02-13 17:16 ESTNewsAtossa announces new U.S. patent covering lead assetN/A
2022-11-08 08:22 ESTNewsAtossa Therapeutics GAAP EPS of -$0.06 in-lineN/A
2022-11-01 22:41 ESTNewsAtossa acquiring ~20% stake in Dynamic Cell Therapies to boost CAR-T developmentN/A
2022-10-24 18:54 ESTNewsAtossa receives FDA OK to begin phase 2 trial of (Z)-endoxifen for breast cancerN/A
2022-10-11 12:37 ESTNewsAtossa Therapeutics: Still Gets An 'Incomplete' RatingN/A
2022-08-08 19:55 ESTNewsAtossa Therapeutics GAAP EPS of -$0.05N/A
2022-06-06 16:58 ESTNewsClover Health, Aurinia Pharma among the top 10 health care additions to Russell 3000 Index, Asensus Surgical, Clovis Oncology among top deletionsN/A
2022-05-10 02:23 ESTNewsAtossa Therapeutics GAAP EPS of -$0.04 beats by $0.02N/A
2022-04-21 01:18 ESTNewsAtossa rebounds after enrollment update on study for COVID-19 therapyN/A
2022-03-09 03:27 ESTNewsAtossa Therapeutics issued patent covering breast cancer therapy endoxifenN/A
2022-03-01 03:13 ESTNewsAtossa Therapeutics GAAP EPS of -$0.18N/A
2021-12-10 10:39 ESTNewsA First Assessment On Atossa TherapeuticsN/A
2021-11-15 21:01 ESTNewsAtossa Therapeutics EPS beats by $0.02N/A
2021-10-01 08:19 ESTNewsAtossa starts enrollment in early-stage trial for COVID-19 therapy targeting long-haulersN/A
2021-09-22 21:41 ESTNewsAtossa Therapeutics: Diversification Into COVID Makes Sense In A Variants WorldN/A
2021-09-02 15:07 ESTNewsAtossa Therapeutics gets approval for mid-stage Endoxifen MBD trial in SwedenN/A
2021-08-14 05:43 ESTNewsAtossa Therapeutics EPS misses by $0.02N/A
2021-07-31 05:09 ESTNewsAtossa falls 10% after convening a special meeting for shareholdersN/A
2021-07-31 05:09 ESTNewsERYTECH Pharma, Allied Healthcare Products leads healthcare gainers; Intec Pharma, Translate Bio among major losersN/A
2021-07-30 09:56 ESTNewsAtossa loses a tenth after convening a special meeting for shareholdersN/A
2021-07-20 19:59 ESTNewsAtossa reaches a two-year high ahead of data readout for breast cancer therapyN/A
2021-07-20 19:58 ESTNewsAtossa Therapeutics shares fall after mid-stage Endoxifen breast cancer study resultsN/A
2021-07-20 19:55 ESTNewsAtossa Therapeutics to be included in the Russell 2000, 3000 indexesN/A
2021-07-20 19:51 ESTNewsAtossa Therapeutics continues rally amid a series of catalystsN/A
2021-07-20 19:45 ESTNewsQuant System Highlight: Investors Following This Are Up 120% In A Month! (Video)N/A
2021-07-20 19:44 ESTNewsAtossa rallies ahead of inclusion in Russell IndexesN/A
2021-07-20 19:43 ESTNewsArcus Bio ranks in top weekly healthcare gainers amid positive domvanalimab data; Biogen hit by Lilly donanemab Breakthrough Therapy tagN/A
2021-07-20 19:39 ESTNewsAtossa Therapeutics: Hope Springs EternalN/A
2021-07-20 19:36 ESTNewsCassava, Annovis among H1 biotech winners while Grayburg, Odonate biggest laggardsN/A
2021-07-20 19:33 ESTNewsAtossa Therapeutics gets regulatory nod for AT-H201 COVID-19 study in AustraliaN/A
2021-07-20 19:27 ESTNewsAtossa Therapeutics: Bear Market Defying Biotech Running Out Of UpsideN/A
2021-07-20 19:26 ESTNewsAtossa in selloff for second straight session after sharp run-up this yearN/A
2021-07-20 19:26 ESTNewsFreeline Therapeutics, Cytokinetics leads healthcare gainers; China SXT Pharmaceuticals, Atossa Therapeutics among major losersN/A
2021-04-17 03:15 ESTNewsAtossa Therapeutics Finds Its Share Price Drifting Between CatalystsN/A
2021-04-09 00:34 ESTNewsAtossa Therapeutics says ovarian cancer patient begins treatment with oral endoxifenN/A
2021-03-31 17:04 ESTNewsAtossa Therapeutics EPS misses by $0.76N/A
2021-03-22 22:55 ESTNewsAtossa Therapeutics prices $50M direct offering; shares fallN/A
2021-03-11 23:43 ESTNewsAtossa gets FDA safe to proceed letter for endoxifen in an ovarian cancer patientN/A
2021-02-25 20:05 ESTNewsAtossa climbs after announcing early-stage data for COVID-19 nasal sprayN/A
2021-02-11 03:16 ESTNewsAtossa hints at potential pipeline additions, provides 2021 strategyN/A
2021-02-10 07:12 ESTNewsZomedica, Nemaura and Senseonics extend premarket gainsN/A
2021-02-06 14:45 ESTNewsAssessing Atossa TherapeuticsN/A
2021-02-04 09:55 ESTNewsAtossa updates on single-patient study for EndoxifenN/A
2021-02-02 22:07 ESTNewsAtossa halts Endoxifen breast cancer study after positive dataN/A
2021-01-06 17:26 ESTNewsAtossa Therapeutics prices ~$25M direct offering, stock -23% PMN/A
2021-01-02 15:09 ESTFinancialsCompany financials have been released.Neutral
2020-12-17 13:49 ESTNewsAtossa Therapeutics prices $14M registered direct offeringN/A
2020-12-13 03:15 ESTFinancialsCompany financials have been released.Neutral

About Atossa Therapeutics, Inc (ATOS):

Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.

ATOS Quotes by TradingView

See Advanced Chart

General

  • Name Atossa Therapeutics, Inc
  • Symbol ATOS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 4
  • Last Split Factor1:12
  • Last Split Date2018-04-20
  • Fiscal Year EndDecember
  • IPO Date2012-11-08
  • Gic SectorHealth Care
  • Gic GroupHealth Care Equipment & Services
  • Gic IndustryHealth Care Equipment & Supplies
  • Gic SubIndustryHealth Care Equipment
  • Web URLhttp://atossatherapeutics.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 21.03
  • Enterprise Value EBITDA 0.09
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.36
  • Return on Assets -58%
  • Return on Equity -104%
  • Earnings Per Share -$2.51
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 193.97 million
  • EBITDA -16713626
  • Analyst Target Price $6.25
  • Book Value Per Share $0.88
View More

Share Statistics

  • Shares Outstanding 71.57 million
  • Shares Float 9.37 million
  • % Held by Insiders 12%
  • % Held by Institutions 6.49%
  • Shares Short 7.06 million
  • Shares Short Prior Month 5.76 million
  • Short Ratio 0.21
  • Short % of Float 10%
  • Short % of Shares Outstanding 10%
View More

Technicals

  • Beta 2.16
  • 52 Week High $5.08
  • 52 Week Low $0.81
  • 50 Day Moving Average 2.95
  • 200 Day Moving Average 2.01
View More

Dividends

  • Dividend Date 2018-04-20
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Atossa Therapeutics, Inc (ATOS) Dividend Calendar:

ATOS's last dividend payment was made to shareholders on April 20, 2018.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Atossa Therapeutics, Inc (ATOS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-13$N/A-$0.34-$0.351.45%
2020-06-302020-08-13$N/A-$0.43-$0.28-53.57%
2020-03-312020-05-13$N/A-$0.32-$0.3917.95%
2019-12-312020-03-26$N/A-$0.26-$0.3321.21%
2019-09-302019-11-13$N/A-$0.36-$0.5230.77%
2019-06-302019-08-13$N/A-$0.80-$0.48-66.67%
2019-03-312019-05-13$N/A-$0.62
2018-12-312019-03-28$N/A-$1.25-$0.63-100%
2018-09-302018-11-13$N/A-$0.64-$0.57-13.27%
2018-06-302018-08-13$N/A-$2.90-$0.56-422.52%
2018-03-312018-05-14$N/A-$0.71-$0.8617.44%
2017-12-312018-03-08$N/A$2.28-$0.84371.43%
2017-09-302017-11-13$N/A-$1.99-$3.4842.86%
2017-06-302017-08-14$N/A-$7.17-$5.28-35.73%
2017-03-312017-05-11$N/A-$5.40
2016-12-312017-03-16$N/A-$12.96-$10.92-18.68%
2016-09-302016-11-14$N/A$0.84-$15.36105.47%
2016-06-302016-08-12$N/A-$9.00-$12.6028.57%
2016-03-312016-05-05$N/A-$13.30
2015-12-312016-03-30$-5337911-$10.80-$27.0060%
2015-09-302015-11-12$772244-$27.02
2015-06-302015-08-06$2.69 million-$20.45
2015-03-312015-05-13$1.87 million-$24.09
2014-09-302014-11-12$3426-$23.81
2014-06-302014-08-12$10000-$23.49
2014-03-312014-05-14$24000-$18.00-$19.809.09%
2013-12-312014-03-27$48000-$27.00-$34.2021.05%
2013-09-302013-11-12$76000-$39.60-$22.50-76%
2013-06-302013-08-14$327000-$30.60-$25.20-21.43%
2013-03-312013-05-15$182000-$25.20-$18.00-40%
2012-12-312013-03-28$99000-$19.80-$19.800%
2012-09-302012-12-20$105000-$18.28

Atossa Therapeutics, Inc (ATOS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Atossa Therapeutics, Inc (ATOS) Chart:

ATOS chart by TradingView

Atossa Therapeutics, Inc (ATOS) News:

Below you will find a list of latest news for Atossa Therapeutics, Inc (ATOS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Atossa Therapeutics, Inc (ATOS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-02-200.50.2CALL0 1580TRUE00
2026-02-2010.05CALL0 00TRUE00
2026-02-201.50CALL0 00TRUE00
2026-02-2020.05CALL0 00TRUE00
2026-02-2032.25CALL0 1215.39TRUE00
2026-02-2041.29CALL1 0220.89TRUE1.290
2026-02-2050.8CALL0 1189.51FALSE00
2026-02-2060.2CALL0 100388.7FALSE00
2026-02-2070CALL0 0456.79FALSE00
2026-02-2080CALL0 0510.02FALSE00
2026-02-2090CALL0 0553.71FALSE00
2026-02-20100.4CALL0 1436.74FALSE00
2026-02-200.50.05PUT0 110FALSE00
2026-02-2010.35PUT0 00FALSE00
2026-02-201.50.85PUT0 60FALSE00
2026-02-2020PUT0 01111.24FALSE00
2026-02-2030.05PUT0 40208.71FALSE00
2026-02-2040PUT0 0479.03FALSE00
2026-02-2050.66PUT1 2191.01TRUE0.110.2
2026-02-2061.25PUT1 0164.83TRUE1.250
2026-02-2070PUT0 0163.63TRUE00
2026-02-2080PUT0 0205.09TRUE00
2026-02-2090PUT0 0239.48TRUE00
2026-02-20100PUT0 0322.17TRUE00
2026-03-200.50.25CALL0 200TRUE00
2026-03-2010.05CALL0 00TRUE00
2026-03-201.50CALL0 00TRUE00
2026-03-2020CALL0 0270.23TRUE00
2026-03-2030CALL0 0168.83TRUE00
2026-03-2040CALL0 0148.1TRUE00
2026-03-2050CALL0 0154.71FALSE00
2026-03-2060CALL0 0136.3FALSE00
2026-03-2070.5CALL0 6241.96FALSE00
2026-03-2080CALL0 0270.28FALSE00
2026-03-2090CALL0 0293.52FALSE00
2026-03-20100CALL0 0313.2FALSE00
2026-03-200.50.11PUT0 40FALSE00
2026-03-2010.41PUT0 00FALSE00
2026-03-201.50PUT0 00FALSE00
2026-03-2020PUT0 0591.63FALSE00
2026-03-2030PUT0 0382.66FALSE00
2026-03-2040.5PUT5 0158.92FALSE0.50
2026-03-2050.8PUT1 2124.44TRUE0.80
2026-03-2060PUT0 0161.24TRUE00
2026-03-2070PUT0 0140.41TRUE00
2026-03-2080PUT0 0157.62TRUE00
2026-03-2090PUT0 0131.86TRUE00
2026-03-20100PUT0 0148.16TRUE00
2026-04-170.50.16CALL0 11950TRUE00
2026-04-1710.05CALL0 0153.27TRUE00
2026-04-171.50.03CALL0 43130TRUE00
2026-04-1720.01CALL0 0164.97TRUE00
2026-04-1730.03CALL0 0127.26TRUE00
2026-04-1740.01CALL0 0126.98TRUE00
2026-04-1750CALL0 0117.34FALSE00
2026-04-1760CALL0 0121.19FALSE00
2026-04-1770.2CALL1 083.6FALSE0.20
2026-04-1780CALL0 0205.76FALSE00
2026-04-1790.5CALL0 1223.52FALSE00
2026-04-17100CALL0 0238.56FALSE00
2026-04-170.50.06PUT0 25620FALSE00
2026-04-1710.45PUT0 00FALSE00
2026-04-171.50.65PUT0 60FALSE00
2026-04-1721.06PUT0 0452.49FALSE00
2026-04-1730PUT0 0292.81FALSE00
2026-04-1740PUT0 0129.33FALSE00
2026-04-1750PUT0 0132.09TRUE00
2026-04-1760PUT0 0118.31TRUE00
2026-04-1770PUT0 0152.26TRUE00
2026-04-1780PUT0 0122.28TRUE00
2026-04-1790PUT0 0138.99TRUE00
2026-04-17100PUT0 0116.52TRUE00
2026-07-170.50.2CALL0 1010TRUE00
2026-07-1714.6CALL0 3181.78TRUE00
2026-07-171.50.05CALL0 3280TRUE00
2026-07-1720.03CALL0 0173.07TRUE00
2026-07-1730.01CALL0 0136.14TRUE00
2026-07-1740.05CALL0 0124.42TRUE00
2026-07-1751.65CALL7 1127.86FALSE-0.15-0.08
2026-07-1760CALL0 0135.61FALSE00
2026-07-1770CALL0 0122.71FALSE00
2026-07-1781.55CALL0 1125.38FALSE00
2026-07-1790.76CALL0 1125.18FALSE00
2026-07-17100.75CALL0 1126.71FALSE00
2026-07-170.50.27PUT0 500FALSE00
2026-07-1710.6PUT0 00FALSE00
2026-07-171.50PUT0 00FALSE00
2026-07-1721.3PUT0 0296.94FALSE00
2026-07-1730.55PUT1 0134.19FALSE0.550
2026-07-1741PUT1 0129.15FALSE10
2026-07-1751.5PUT0 2116.27TRUE00
2026-07-1760PUT0 0113.91TRUE00
2026-07-1770PUT0 0117.48TRUE00
2026-07-1780PUT0 0124.65TRUE00
2026-07-1790PUT0 0120.98TRUE00
2026-07-17100PUT0 0131.32TRUE00

Latest ATOS Trades:

Date Shares Price
Jun 13, 2022 7:57 PM EST180$1.055
Jun 13, 2022 7:58 PM EST100$1.055
Jun 13, 2022 7:59 PM EST100$1.055
Jun 13, 2022 7:59 PM EST100$1.055
Jun 13, 2022 7:59 PM EST100$1.055

Atossa Therapeutics, Inc (ATOS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920011265/0001437749-20-011265-index.htm
2018-04-06UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1488039/000000000018010515/0000000000-18-010515-index.htm
2018-04-25UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1488039/000000000018012803/0000000000-18-012803-index.htm
2018-06-12UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1488039/000000000018018066/0000000000-18-018066-index.htm
2020-09-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1488039/000000000020008409/0000000000-20-008409-index.htm
2017-10-31SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000090266417004121/0000902664-17-004121-index.htm
2018-01-19SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000090266418000311/0000902664-18-000311-index.htm
2017-11-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000093041317003736/0000930413-17-003736-index.htm
2018-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000093041318000510/0000930413-18-000510-index.htm
2018-04-27SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000121390018005062/0001213900-18-005062-index.htm
2019-02-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000121390019001898/0001213900-19-001898-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774918020569/0001437749-18-020569-index.htm
2018-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000143774918020638/0001437749-18-020638-index.htm
2019-01-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919000870/0001437749-19-000870-index.htm
2019-03-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1488039/000143774919005927/0001437749-19-005927-index.htm
2019-03-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919005929/0001437749-19-005929-index.htm
2019-04-12DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1488039/000143774919007053/0001437749-19-007053-index.htm
2019-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919009664/0001437749-19-009664-index.htm
2019-05-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000143774919009666/0001437749-19-009666-index.htm
2019-05-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919010399/0001437749-19-010399-index.htm
2019-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774919010644/0001437749-19-010644-index.htm
2019-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774919010645/0001437749-19-010645-index.htm
2019-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774919010646/0001437749-19-010646-index.htm
2019-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774919010647/0001437749-19-010647-index.htm
2019-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774919010648/0001437749-19-010648-index.htm
2019-06-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919012879/0001437749-19-012879-index.htm
2019-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000143774919016448/0001437749-19-016448-index.htm
2019-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919016451/0001437749-19-016451-index.htm
2019-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919020029/0001437749-19-020029-index.htm
2019-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000143774919022613/0001437749-19-022613-index.htm
2019-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919022614/0001437749-19-022614-index.htm
2020-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920000245/0001437749-20-000245-index.htm
2020-02-07424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1488039/000143774920002083/0001437749-20-002083-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920002085/0001437749-20-002085-index.htm
2020-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920006154/0001437749-20-006154-index.htm
2020-03-2610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1488039/000143774920006155/0001437749-20-006155-index.htm
2020-04-13DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920007556/0001437749-20-007556-index.htm
2020-04-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920007600/0001437749-20-007600-index.htm
2020-04-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920007628/0001437749-20-007628-index.htm
2020-04-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920007630/0001437749-20-007630-index.htm
2020-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920010512/0001437749-20-010512-index.htm
2020-05-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000143774920010514/0001437749-20-010514-index.htm
2020-05-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920011257/0001437749-20-011257-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920011261/0001437749-20-011261-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920011262/0001437749-20-011262-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920011263/0001437749-20-011263-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920011264/0001437749-20-011264-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920011265/0001437749-20-011265-index.htm
2020-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920017737/0001437749-20-017737-index.htm
2020-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000143774920017738/0001437749-20-017738-index.htm
2020-09-02S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1488039/000143774920019223/0001437749-20-019223-index.htm
2020-09-08CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1488039/000143774920019381/0001437749-20-019381-index.htm
2020-09-25424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1488039/000143774920020266/0001437749-20-020266-index.htm
2020-09-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920020267/0001437749-20-020267-index.htm
2017-11-03SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000155335017001165/0001553350-17-001165-index.htm
2017-11-03SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000155335017001167/0001553350-17-001167-index.htm
2017-10-26424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1488039/000161577417005904/0001615774-17-005904-index.htm
2017-10-27424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1488039/000161577417005964/0001615774-17-005964-index.htm
2017-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577417005989/0001615774-17-005989-index.htm
2017-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000161577417006519/0001615774-17-006519-index.htm
2017-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577417006627/0001615774-17-006627-index.htm
2017-11-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577417006777/0001615774-17-006777-index.htm
2017-12-21424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1488039/000161577417007507/0001615774-17-007507-index.htm
2017-12-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577417007555/0001615774-17-007555-index.htm
2018-02-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418000770/0001615774-18-000770-index.htm
2018-02-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418001342/0001615774-18-001342-index.htm
2018-03-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418001692/0001615774-18-001692-index.htm
2018-03-0810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1488039/000161577418001693/0001615774-18-001693-index.htm
2018-03-08PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418001705/0001615774-18-001705-index.htm
2018-03-20DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418001985/0001615774-18-001985-index.htm
2018-03-27S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1488039/000161577418002120/0001615774-18-002120-index.htm
2018-04-02DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1488039/000161577418002285/0001615774-18-002285-index.htm
2018-04-16DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1488039/000161577418002644/0001615774-18-002644-index.htm
2018-04-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418002666/0001615774-18-002666-index.htm
2018-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418002808/0001615774-18-002808-index.htm
2018-04-23S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/0001615774-18-002813-index.htm
2018-04-23CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1488039/000161577418002815/0001615774-18-002815-index.htm
2018-05-03S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1488039/000161577418003227/0001615774-18-003227-index.htm
2018-05-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1488039/000161577418003229/0001615774-18-003229-index.htm
2018-05-07CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1488039/000161577418003390/0001615774-18-003390-index.htm
2018-05-07CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1488039/000161577418003391/0001615774-18-003391-index.htm
2018-05-10424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1488039/000161577418003583/0001615774-18-003583-index.htm
2018-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000161577418003668/0001615774-18-003668-index.htm
2018-05-16FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418003930/0001615774-18-003930-index.htm
2018-05-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418003978/0001615774-18-003978-index.htm
2018-05-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418004587/0001615774-18-004587-index.htm
2018-05-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418004655/0001615774-18-004655-index.htm
2018-05-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418004657/0001615774-18-004657-index.htm
2018-05-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418004659/0001615774-18-004659-index.htm
2018-06-04S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1488039/000161577418004829/0001615774-18-004829-index.htm
2018-06-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1488039/000161577418005158/0001615774-18-005158-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418005994/0001615774-18-005994-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418005995/0001615774-18-005995-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418005996/0001615774-18-005996-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418005997/0001615774-18-005997-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418005998/0001615774-18-005998-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418006000/0001615774-18-006000-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418006001/0001615774-18-006001-index.htm
2018-07-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418006119/0001615774-18-006119-index.htm
2018-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418007922/0001615774-18-007922-index.htm
2018-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000161577418007923/0001615774-18-007923-index.htm
2018-09-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418009490/0001615774-18-009490-index.htm
2018-11-1310-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000161577418012549/0001615774-18-012549-index.htm
2019-01-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577419000644/0001615774-19-000644-index.htm
2019-01-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577419000645/0001615774-19-000645-index.htm
2018-05-09EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1488039/999999999518001185/9999999995-18-001185-index.htm
2018-06-14EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1488039/999999999518001509/9999999995-18-001509-index.htm
2020-09-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1488039/999999999520002415/9999999995-20-002415-index.htm

Atossa Therapeutics, Inc (ATOS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Atossa Therapeutics, Inc (ATOS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 12%
Institutional Ownership: 649%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2017-11-15Kyle GuseCFO, Gen Counsel and SecretaryBuy1,400.000.34471.1010,000.00https://www.sec.gov/Archives/edgar/data/1488039/000161577417006777/0001615774-17-006777-index.htm
2017-11-15Kyle GuseCFO, Gen Counsel and SecretaryBuy8,600.000.342,898.208,600.00https://www.sec.gov/Archives/edgar/data/1488039/000161577417006777/0001615774-17-006777-index.htm